Taken together, these findings suggest that ASPP2 overexpression might represent a novel strategy for hepatocyte survival by decreasing the level of TGs in the treatment of NAFLD. The gene discussed is TP53BP2; the disease is metabolic dysfunction-associated steatotic liver disease.